SPY763.59QQQ736.11−0.25%BTC/USD83,832.61+0.24%DIA512.05−0.16%GLD383.11+0.06%TLT78.47+0.31%
Benzinga

Capricor Therapeutics Inc

CAPRNASDAQ
Trade with Public
Trade with Public
$8.57
-0.14-1.61%
At close: Sep 28, 5:00 PM EST
$9.67
0.9611.02%
Pre-Market: 7:15 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Capricor Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Capricor Therapeutics (CAPR).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

7Buy
2Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$31Upside to Avg. PT+219.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 14, 2026B. Riley SecuritiesMadison El-SaadiUpgradeNeutral→Buy$5→$21
Sep 1, 2026Piper SandlerEdward TenthoffUpgradeNeutral→Overweight$2→$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
Benzinga Newsdesk

PRO
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
Benzinga Newsdesk

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Avi Kapoor

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved